Evaluating ASC and Fibringlue for Crohn's Fistula Treatment

Phase 3 Clinical Study to Evaluate Efficacy and Safety of ASC(Autologous Adipose-derived Stem Cells) and Fibringlue or Fibringlue in Patients With Crohn's Fistula.: A Randomized Study

This study is testing whether a new treatment using fat-derived stem cells along with a special glue can help people with Crohn's fistulas heal better than just using the glue alone.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 36 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Anterogen Co., Ltd. (Industry-sponsored)
• Drugs / interventions: infliximab, adalimumab, certolizumab
• Locations: 3 sites (Seoul and 2 other locations)
• Trial ID: NCT04612465 on ClinicalTrials.gov

What this trial studies

This phase III clinical study aims to assess the efficacy and safety of autologous adipose-derived stem cells (ASC) combined with Fibringlue compared to Fibringlue alone in patients suffering from Crohn's fistula. The study employs a randomized interventional design to determine the best treatment approach for this challenging condition. Participants will be monitored for their response to the treatment and any potential side effects throughout the study duration.

Who should consider this trial

Good fit: Ideal candidates are individuals diagnosed with Crohn's disease who have one or more Crohn's fistulas.

Not a fit: Patients with autoimmune diseases other than Crohn's disease or those with a history of certain medical conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve healing outcomes for patients with Crohn's fistula.

How similar studies have performed: While similar approaches using stem cells have shown promise in other studies, this specific combination of ASC and Fibringlue is relatively novel.

Eligibility criteria

Inclusion Criteria:

1. Patient who has obtained the consent of their legal representative if they are over 18 years of age and under 20 years of age.
2. Patient is diagnosed with Crohn's disease.
3. Patient who has one or more Crohn's fistulas .
4. In the case of women of childbearing potential, patient who is negative for beta-HCG pregnancy tests at the screening visit.
5. Patient is able to give written informed consent prior to study start and willing to comply with the study requirements.

Exclusion Criteria:

1. Patient who participated in other clinical trials within 30 days prior to the start of this clinical trial, or who has not passed a period equal to five times of the half-life of the drug dosed in other clinical trials.
2. Patient with a medical history or family history of Variant Creutzfeld Jakob Disease or related to this disease.
3. Patient who is sensitive to anesthetic drugs or bovine-derived materials.
4. Patient with autoimmune disease except for Crohn's disease.
5. Patient with infectious diseases such as HBV, HCV and HIV.
6. Patient with signs of Septicemia.
7. Patient with Active Tuberculosis.(Including patient with Anal Tuberculosis)
8. Pregnant or breast-feeding.
9. . Is unwilling to use an acceptable method of birth control during the whole study.
10. Patient with Inflammatory Bowel disease except for Crohn's disease.
11. Patient who is sensitive to Fibringlue.
12. Patient with a clinically relevant history of alcohol or drugs abuse, habitual smoking.
13. Patient whose adipose tissue obtained by liposuction is insufficient to manufacture the Investigational product at the intended dose.
14. Patient who is not able to understand the objective of the study or to comply with the study requirements.
15. Patient who is considered by the investigator to have a significant disease which might impact the study.
16. Patient who is considered not suitable for the study by investigator.
17. Patient who is Active Crohn's disease with CDAI 450 or higher.
18. Patient with medical history of surgery for malignant cancer in the past 5 years.(Except for carcinoma in situ)
19. Patient who exceeds 2 cm in the longest diameter of fistula.
20. Patient who dosed anti-TNF formulations such as infliximab, adalimumab, certolizumab within 3 months prior to injection.

Where this trial is running

Seoul and 2 other locations

• Seoul Natinoal Univetsity Hospital — Seoul, Korea, Republic of (Recruiting)
• Asan Medical Center — Seoul, Korea, Republic of (Recruiting)
• Samsung Medical Center — Seoul, Korea, Republic of (Recruiting)

Study contacts

• Principal investigator: KyuJoo Park, MD. Ph D — Seoul National University Hospital
• Study coordinator: KyuJoo Park, MD. Ph D

Conditions Crohn's Fistula